Have you and your family had your flu shot? It's more important than ever this year! Schedule via MyChart or call for an appointment in SF, the East Bay or San Mateo.

About me

Dr. Peter Sayre specializes in adult bone marrow transplantation and other treatments for leukemia, multiple myeloma, lymphoma and Hodgkin's disease.

Sayre is a director of clinical research at UCSF. His research interests focus on allogeneic stem cell transplants (which use cells from a matching donor) and leukemia in older adults. His work on these subjects has been widely published in medical and other scientific journals.

Sayre earned an undergraduate degree in philosophy from Yale College, graduating magna cum laude. He earned his medical degree at the Rutgers Robert Wood Johnson Medical School, and he earned a doctorate in immunology at Harvard University. He completed a fellowship in hematology and oncology at UCSF before joining the faculty in 1996.

  • Education

    Robert Wood Johnson Medical School, 1990

  • Residencies

    UC San Diego, Internal Medicine, 1993

  • Fellowships

    UCSF, Oncology, 1996

    UCSF, Hematology, 1996

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews

4.8

Overall Experience
41 Reviews
Dr Sayre was excellent. Very thorough and communicates well!
Explained things in a way that was easy to understand
40 Reviews
Did the doctor pay attention to your concerns
41 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
39 Reviews
Knew the important information about your medical history
41 Reviews
The provider showed respect for what you had to say
41 Reviews
The provider spent enough time with me
41 Reviews
Decorative Caduceus

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (A...

Proportion of patients achieving a best response of CR (morphologic CR [mCR], cytogenetic CR [CRc], molecular CR [CRm], or CRh per Interworking Group AML response criteria.

Recruiting

Share